DIAGONAL BIO Aktie

 

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that, effective Monday, 28 April 2025, the Company will transition its news distribution service from Cision News to Modular Finance (MFN). Starting from Monday 28 of April, those wishing to subscribe to Diagonal Bio's news updates can register on the Company's website (https://diagonalbio.com/news-press/). Please note that the system does not allow for subscribers to be transferred from Cision to MFN automatically. All current subscribers are kindly requested to re-subscribe on the Company's website. For additional...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") is pleased to announce that Diagonal Bio has signed an agreement to conduct pilot tests of the LAMPlify® platform at Stall Törnqvist as well as an undisclosed additional facility. Set to begin in April 2025, the pilot tests will run for three and six months, respectively and aim to improve equine health by enabling the early detection of potential viral infections in horses, ultimately enhancing their overall performance and well-being. Stall Törnqvist, run by Maria Törnqvist, was founded in 2016 and currently houses 100 horses. The...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") hereby publishes its year-end report for the financial year 2024. Below is a brief summary. The full year-end report is available on Diagonal Bio's website (www.diagonalbio.com) and as an attached file. Summary of the year-end report for 2024   2024-10-01 — 2024-12-31 (October— December 2024) · Net sales amounted to 62 KSEK (23 KSEK), capitalised development contributed with 281 KSEK (405 KSEK), and other operating income amounted to 1 KSEK (7 KSEK). · Operating loss amounted to -2 260 KSEK (-2 530 KSEK). · Operating...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that the Japanese Patent Office has confirmed the grant of a patent (application number: EP3987059B1) to Diagonal Bio for the Company's key technology ('A DNA/RNA detection platform'). At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia. “The granted patent in Japan further strengthens our position and protection. We are continuously working to protect...

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025. According to the instructions for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three largest shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting...

Today, 19 March 2025, is the first day of trading in Diagonal Bio AB's (publ) ("Diagonal Bio" or "the Company") securities on NGM Nordic SME (“NGM”). The shares are traded with ISIN code SE0015961826 under the ticker DIABIO, the warrants of series TO 2 are traded with ISIN code SE0023615968 under the ticker DIABIO TO2. The shareholders do not need to take any action in connection with the change of marketplace. “The decision to change marketplace was based on the evaluation that the move to NGM will result in lower costs and possibilities for us to allocate more capital to marketing and...

Nordic Growth Market NGM AB (“NGM“) has, as previously announced, decided to list the shares in Diagonal Bio AB at NGM. The warrants of series TO2 issued by Diagonal Bio AB are also approved for listing, the first day of trading has been set to March 19, 2025.   Information regarding the affected instrument:   Listing name: Diagonal Bio TO2 Exchange symbol: DIABIO TO2 ISIN-code: SE0023615968 CFI-code: RSSXXR FISN-code: DIAGONALBI/OPT RTS 20250618 Instrument-ID: H6QH Tick size table/liquidity band: A Number of issued warrants: 361 889 384 First day of...

Nordic Growth Market NGM AB (“NGM“) has, as previously announced, decided to list the shares in Diagonal Bio AB at NGM. The first day of trading has been set to March 19, 2025.   Information regarding the affected instruments:   Listing name: Diagonal Bio Exchange symbol: DIABIO ISIN-code: SE0015961826 CFI-code: ESVUFR FISN-code: DIAGONALBI/SH Instrument-ID: H5VY Tick size table/liquidity band: 3 Number of issued shares: 1 214 965 327 First day of trading: 2025-03-19 Market-ID: NSME Segment-ID: NSSE   For more information about this Market...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") and Stall Courant, owned by Unibet founder Anders Ström and run by trotting trainer Sabine Kagebrant, have signed an agreement regarding a three-month pilot test of the LAMPlify® platform. Stall Courant, founded in 2005 and located in Heby, Sweden, is home to 35 trotting horses and also operates a breeding program. Sabine Kagebrant joined Stall Courant in 2014 and has served as CEO since 2016. Together with the trotting horse Joviality, Kagebrant has secured victories in several major races. "We at Stall Courant are excited to work...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market (“First North”). The last day of trading on First North is 18 March 2025 and the Company will instead be listed on NGM Nordic SME (“NGM”) with a planned first day of trading on 19 March 2025, provided that no new information emerges that affects the listing. The granting of the delisting application is conditioned by Diagonal Bio fulfilling the formal listing requirements of NGM and thus, that the securities in...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME (“NGM”). The first day of trading is planned for 19 March 2025. This means that Diagonal Bio changes marketplace from Nasdaq First North Growth Market (“First North”). The decision is conditioned by Diagonal Bio fulfilling the formal listing requirements and that no new information emerges that affects the Company's fulfilment of these requirements. Due to the conditional approval, Diagonal Bio has applied for delisting from First North with a desired last day of...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that the Company – in order to be able to reallocate costs – has decided to apply for listing on NGM Nordic SME (“NGM”). The decision is based on the evaluation that the move from Nasdaq First North Growth Market to NGM will result in lower costs and thus possibilities for Diagonal Bio to allocate more of the available capital to marketing and sales. Diagonal Bio has been listed on Nasdaq First North Growth Market since July 2021. The objective is to complete the move during March 2025. For additional information...

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of the successful completion of the pilot test which started in October 2024 and includes the purchase of LAMPlify® along with associated consumables. On 3rd October 2024, Diagonal Bio announced its partnership with StallZet and Daniel Redén, to conduct a three-month pilot test using LAMPlify to detect respiratory viral infections in StallZet's trotters. StallZet is one of Sweden's leading horse...

Today, 23 January 2025, the subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6 million, with preferential rights for the Company's existing shareholders, commences (the "Rights Issue"). The subscription period runs until 6 February 2025. The Rights Issue was resolved upon by the Board of Directors on 23 December 2024 and approved by the Extraordinary General Meeting on 17 January 2025, together with the resolution on a directed issue of units (the “Directed Issue”, together, the Rights Issue and the Directed Issue...

The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on a directed issue of units, commences tomorrow, 23 January 2025. The Company has prepared an investment memorandum, containing information about the Company as well as about the rights issue of units and the terms and conditions for the rights issue. The investment memorandum is available on Diagonal Bio's website (www.diagonalbio.com). Press release 22 January 2025     NOT FOR RELEASE,...

Das Instrument 9F1 SE0015961826 DIAGONAL BIO AB EQUITY wird ex Kapitalmassnahme gehandelt am 20.01.2025 The instrument 9F1 SE0015961826 DIAGONAL BIO AB EQUITY is traded ex capital adjustment on 20.01.2025...

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025. According to the instructions for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three largest shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting...

Today, January 17, 2025, an Extraordinary General Meeting was held in Diagonal Bio AB. A summary of the adopted resolutions follows below. Resolution on reduction of the share capital for allocation to non-restricted equity The general meeting resolved, in accordance with the board of directors' proposal, to reduce the company's share capital by a maximum of SEK 7,659,877.37 for allocation to non-restricted equity and without cancellation of shares. The effect of the resolution on a reduction of the share capital is that the share capital and restricted equity will be reduced by a maximum...

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces the expansion of its equine diagnostic testing panel to include the detection of Equine Herpesvirus type 5 (EHV-5), following the recommendation of Daniel Redén – Diagonal Bio's marketing partner and a renowned horse trainer. Diagonal Bio successfully developed, tested, and validated in-house the EHV-5 detection capability within three weeks. Diagonal Bio announced on 3rd October 2024 that horse trainer Daniel Redén from StallZet will conduct a pilot using the LAMPlify® platform to test for equine viruses. This collaboration...

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Daniel Redén, a renowned horse trainer at StallZet, has entered into a partnership with Diagonal Bio and will act as a marketing partner for the Company to enhance the commercialisation plans for the Company's platform, LAMPlify®️. StallZet, one of Sweden's leading trotting facilities with over 190 horses, is collaborating with Diagonal Bio in the ongoing pilot test of LAMPlify®️. As a marketing partner to Diagonal Bio, Daniel Redén will play a key role in showcasing the benefits of LAMPlify® and promoting the product....